Monday, March 8, 2021

PRESS RELEASES

Coronavirus: FDA Authorizes First Point-of-Care Antibody Test

Coronavirus (COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19

SILVER SPRING, Md., Sept. 23, 2020 /PRNewswire/ — Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care (POC) test for COVID-19. The Assure COVID-19 IgG/IgM Rapid Test Device was first authorized for emergency use by certain labs in July 2020 to help identify individuals with antibodies to SARS-CoV-2, indicating recent or prior COVID-19 infection. Today, that EUA is being reissued to authorize the test for POC use using fingerstick blood samples. This authorization means that fingerstick blood samples can now be tested in POC settings like doctor’s offices, hospitals, urgent care centers and emergency rooms rather than having to be sent to a central lab for testing.

“Authorizing point-of-care serology tests will enable more timely and convenient results for individuals who want to understand if they have previously been infected with the virus that causes COVID-19,” said FDA Commissioner Stephen M. Hahn, M.D. “Until today, serology test samples were generally only able to be evaluated in a central lab, which can be time consuming and use additional resources to transport samples and run the test. As more and more point-of-care serology tests are authorized, they will help conserve those resources and may help reduce processing time for other types of COVID-19 tests, as less time is spent on serology tests.”

Nearly 50 serology tests have been granted an EUA since the start of the pandemic. The Assure test is a lateral flow assay and is authorized for use with venous whole blood, serum, plasma and fingerstick whole blood. This serology POC test, unlike POC COVID-19 diagnostic tests, uses a blood sample from the fingertip to run the test.

The FDA wants to remind patients that it is unknown how long antibodies persist following infection and if the presence of antibodies confers protective immunity, so they should not interpret results from a serology test as telling them they are immune, or have any level of immunity, from the virus. Due to these unknowns, the FDA cautions patients against using the results from these tests, or any serology test, as an indication that they can stop taking steps to protect themselves and others, such as stopping social distancing, discontinuing wearing masks or returning to work.

The FDA also wants to remind the public that serology tests should not be used to diagnose an active infection, as they only detect antibodies the immune system develops in response to the virus – not the virus itself. It is also important to remember that in a population with low prevalence, even high-performing antibody tests may produce as many or more false results as true results because the likelihood of finding someone who has been infected is very small. Thus, it is necessary to consider that the results from two serology tests may be needed to generate reliable results. 

The Assure COVID-19 IgG/IgM Rapid Test Device is currently the only FDA authorized COVID-19 POC serology test and is available by prescription only. The FDA continues to work with test developers to expand access to COVID-19 testing.

Media Contact: Jim McKinney, 240-328-7305
Consumer Inquiries: 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

SOURCE U.S. Food and Drug Administration

- Advertisement -

PATIENT ADVISORY

Medika Life has provided this material for your information. It is not intended to substitute for the medical expertise and advice of your health care provider(s). We encourage you to discuss any decisions about treatment or care with your health care provider. The mention of any product, service, or therapy is not an endorsement by Medika Life

Medika Lifehttps://medika.life
Medika Life is a digital Health Publication for both the medical profession and the public. Make informed decisions about your health and stay up to date with the latest developments and technological advances in the fields of medicine.

Read more Releases

HealthTap Introduces Virtual Primary Care that Prioritizes Uninsured and Underinsured Populations in the U.S.

Because HealthTap connects patients with doctors using their dynamic matching technology, it’s extremely efficient and therefore low-cost virtual care

Texas Food Relief with NCS Group and #BStrong Initiative Deliver Food Aid Across Texas

Each NCS Group Unlimited Carrier Fleet Vehicle brings a total of $180K+ worth of supplies and aid, and a total of six trucks are arriving in Texas

Global Empowerment Mission in Partnership with Bethenny Frankel’s BStrong Initiative Align with NCS Group for Texas Aid Relief During The State of Emergency

The LATEST mission is bringing three relief trucks to Texas with the first truck en route from Miami to Denton (The Cross Timbers Hope Center In Denton, TX) followed by Houston, TX on Tuesday (February 23)

NLR. Millions at Risk from Leprosy. Study Reveals Figures

To interrupt leprosy transmission and reduce annual new cases significantly, preventive treatment needs to be implemented in all leprosy-endemic countries

Qatar Genome Research Consortium Reports First and Largest Comprehensive Genetic Association Study in Middle East

A group of researchers at Qatar Foundation have reported the first and largest genetic association study in the Middle East, that has been published online in Nature Communications

South University Announces New MSPA Program at West Palm Beach Campus

South University is proud to announce the launch of a new Master of Science in Physician Assistant (“MSPA”) program at the West Palm Beach campus located in Royal Palm Beach, Florida

RECENT PRESS RELEASES

NEED MORE EXPOSURE?

Want your companies products and services advertised across Medika's platform? We offer various packages from a free 3 month trial to an Enterprise package for larger companies fielding multiple brands,

%d bloggers like this: